Richtlijnen - AZ Sint-Lucas

) in eerste lijn combinatie triple chemotherapie : FOLFIRINOX. Deze mogelijkheid is
in België niet terugbetaald.
Phase 3 results of the PRODIGE 4/ACCORD 11 trial that enrolled 342 patients
between 2005 and October 2009. Patients were all chemotherapy-naive, aged 18
to 75 years (median 61 years), and had histologically/cytologically confirmed
metastatic pancreatic adenocarcinoma. In addition, all patients had to have a
performance status of zero or one.The patients were randomly assigned
gemcitabine or FOLFIRINOX. The preplanned interim analysis was conducted by
an independent data monitoring committee in September. At this time, it
recommended to stop the study.Data indicated that patients on the FOLFIRINOX
regimen had improved response (31.6% vs. 9.4%; P=.0001) and improved disease
control (70.2% vs. 50.9%; P=.0003) compared with gemcitabine.In addition,
FOLFIRINOX significantly extended the median PFS (6.4 months vs. 3.3 months;
P